# Clade Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/clade-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.cladetx.com
- Total disclosed funding: $46M
- Latest round: Series A (Aug 11, 2021)
- Investors on record: 4

## About

Founded in 2020 and based in Massachusetts, US, Clade Therapeutics, Inc. operates as a clinical drug development company that develops drugs for patients with cancer diseases. The company was founded by its CEO, Chad Cowan, CBO Jim Glasheen, Deepta Bhattacharya, and Gustavo Mostoslavsky. In April 2024, Century Therapeutics, Inc., a portfolio company of Avidity Partners, Venrock Healthcare Capital Partners, and DAFNA Capital Management, acquired Clade Therapeutics, Inc. from Bristol-Myers Squibb Company, Emerson Collective, LifeSci Partners, and Syncona Limited for USD 35 million. The company will receive an additional USD 10 million upon reaching certain milestones.

Clade develops cell medicines, mainly iPSC-derived cells, to treat cancer and autoimmune diseases. The company offers an aß iT platform, which is an iPSC-derived cell therapy that provides iPSC-derived aß T cells. The company uses induced pluripotent stem cells (iPSCs) to create adult human T cells, Treg cells, and B cells. These cells can be used to target and destroy cancer cells or suppress autoimmune responses. The firm’s pipeline program includes CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating cancer, which have a combination of iPSC-derived CD8+ and CD4+ aß CAR-T cells.

## Funding rounds

- Series A, Aug 11, 2021, $46M — Bristol-Myers Squibb Company, Syncona, Emerson Collective, LifeSci Partners

## Investors

- Bristol-Myers Squibb Company — Series A
- Syncona (https://capitalatlas.ai/funds/syncona) — Series A
- Emerson Collective — Series A
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series A